Application of compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs

A tyrosine kinase, anti-tumor drug technology, applied in the field of medicine, can solve the problems of increasing the level of ROS, reducing the level of MDA, and undisclosed anti-tumor activity of resveratrol

Inactive Publication Date: 2018-12-07
黄泳华
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Damiano S et al. (J Cell Biochem. 2018 Jun; 119(6):4845-4854. Reference 5) reported that antioxidants including resveratrol can significantly reduce the induction of dasatinib or nilotinib The level of MDA in K562 cells was significantly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs
  • Application of compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs
  • Application of compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Embodiment 1 comprises the preparation of the capsule of resveratrol and imatinib mesylate (molar ratio is 1:1)

[0066] prescription

[0067]

[0068] Preparation

[0069] Take the prescribed amount of resveratrol, imatinib mesylate, microcrystalline cellulose and sodium stearyl fumarate, mix them thoroughly, fill capsules, and subpackage.

Embodiment 2

[0070] Embodiment 2 comprises the preparation of the tablet of resveratrol and gefitinib (molar ratio is 13.375:1)

[0071] prescription

[0072]

[0073] Preparation

[0074] Take the prescribed amount of resveratrol, gefitinib, microcrystalline cellulose, and sodium stearyl fumarate, mix well, and compress into tablets.

Embodiment 3

[0075] Embodiment 3 comprises the preparation of the granule of resveratrol and erlotinib hydrochloride (molar ratio is 25.75:1)

[0076] prescription

[0077]

[0078] Preparation

[0079] Take the prescribed amount of resveratrol, erlotinib hydrochloride, microcrystalline cellulose, sodium stearyl fumarate, fully mix, and pack.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. The application is characterized in that the tyrosine kinase inhibitor is selected from one of imatinib, gefitinib, erlotinib hydrochloride tablets, sorafenib, dasatinib tablets and tasigna or pharmaceutically acceptable salts or solvates or pharmaceutically acceptable salt solvents thereof; the tumor is selected from one of gastric cancer, liver cancer, lung cancer, kidney cancer, cervical cancer, pancreatic cancer, breast cancer, esophagus cancer, nasopharynxcancer and ovarian cancer; the mole ratio of resveratrol to tyrosine kinase inhibitor is (1-100):1.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of a composition containing a tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. Background technique [0002] Tumors are a great threat to human health, and anti-tumor drug research is a very challenging and significant field in today's life sciences. In recent years, with the in-depth study of tumor pathogenic mechanisms, the basic process of signal transduction pathway changes in tumor cells is being gradually elucidated. Using key kinases in some cell signal transduction pathways as drug screening targets to discover new targeted drugs with high efficiency, low toxicity and strong specificity has become one of the effective ways for anticancer drug research today. At present, among all pharmacological targets, it is estimated that more than 1 / 4 of the targets are protein kinases, and it is as high as 75% in the field of anti-tumor, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/05A61K31/506A61K31/44A61K31/5377A61K31/517A61P35/00
CPCA61K31/05A61K31/44A61K31/506A61K31/517A61K31/5377A61K45/06A61P35/00A61K2300/00
Inventor 向飞卢剑飞孙伟光
Owner 黄泳华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products